QuantaMatrix Inc.

QuantaMatrix Inc. is a South Korean in-vitro diagnostics (IVD) company headquartered in Seoul and founded in 2010 as a spin-off from the Biophotonics and Nano Engineering Lab (BiNEL) at Seoul National University, led by Dr. Sunghoon Kwon, a professor in the Department of Electrical and Computer Engineering. The company focuses on microbiology diagnostics, specifically the problem of antimicrobial misuse and the need for faster, targeted antibiotic prescribing in severe infections such as sepsis. QuantaMatrix's flagship offering is dRAST™ (direct & Rapid Antimicrobial Susceptibility Test), a phenotypic, MIC-based antimicrobial susceptibility testing system that works directly from positive blood culture samples. According to the company, dRAST can deliver results in as little as four hours, reducing time to results by up to two days compared with conventional AST workflows, which typically require blood culture, pure culture isolation, identification, and susceptibility testing and can take more than 60 hours or three business days. The system uses microfluidic and microscopic imaging technology to eliminate the need for a pure isolate, and it supports random access with up to 12 samples simultaneously across 15 panel positions, with an on-board expert system offering a choice of guidelines. Two panels are offered, one for Gram-negative and one for Gram-positive organisms. The company positions dRAST as a clinical and socioeconomic solution: faster targeted therapy can improve patient survival in sepsis, reduce inappropriate antibiotic use and antimicrobial resistance, and shorten hospital length of stay. QuantaMatrix states that its microbial diagnostics solutions were the first to be developed in Korea and have received honors including New Excellent Technology (NET) certification (2018.08.23–2025.08.22) and new medical technology certification. Its products are available in European markets through global partners, and the company has received support from CARB-X, including a $2.85 million award for its neonatal sepsis diagnostic platform. QuantaMatrix has also been recognized in Poland, winning a sepsis tender from the Great Orchestra of Christmas Charity (WOŚP). Beyond dRAST, QuantaMatrix has a pipeline that includes QDST™, described as a rapid diagnostic product. The company continues to develop and commercialize rapid microbiology diagnostics aimed at hospitals and clinical laboratories, with a focus on bloodstream infections and sepsis.

QuantaMatrix Inc. was founded in 2010 as an in-vitro diagnostics company. It originated as a spin-off from the Biophotonics and Nano Engineering Lab (BiNEL) at Seoul National University, led by Dr. Sunghoon Kwon, a professor in the Department of Electrical and Computer Engineering. The company was established to commercialize microbiology diagnostics that address the misuse of antibiotics and the need for faster, targeted antimicrobial therapy. The company's core focus became sepsis, a life-threatening condition with a mortality rate of more than 40% where every hour of delay in appropriate treatment increases mortality risk by seven to nine percent. Conventional antimicrobial susceptibility testing (AST) follows blood culture, pure culture, identification, and susceptibility testing, taking over 60 hours or three business days. QuantaMatrix developed dRAST™ (direct & Rapid Antimicrobial Susceptibility Test), which uses microfluidic and microscopic imaging technology to eliminate the need for a pure isolate and deliver MIC-based phenotypic AST results directly from positive blood culture in as little as four hours, reducing time to results by up to two days. QuantaMatrix states that its microbial diagnostics solutions were the first to be developed in Korea and have received the highest honors, including New Excellent Technology (NET) certification (2018.08.23–2025.08.22) and new medical technology certification. The company has expanded its commercial reach through global partners, with products available in European markets. It has received support from CARB-X, including a $2.85 million award for its neonatal sepsis diagnostic platform, and won a sepsis tender from the Great Orchestra of Christmas Charity (WOŚP) in Poland. Its technology has been backed by a research paper in Nature, and the company describes dRAST as the world's fastest antimicrobial testing technology. In addition to dRAST, QuantaMatrix has a pipeline that includes QDST™, a rapid diagnostic product. The company continues to develop and commercialize rapid microbiology diagnostics for hospitals and clinical laboratories, with a focus on bloodstream infections and sepsis.

• 2018

  New Excellent Technology (NET) certification awarded (2018.08.23–2025.08.22).

• 2010

  QuantaMatrix founded as an in-vitro diagnostics company, spin-off from BiNEL at Seoul National University.

• CARB-X awards $2.85 million to QuantaMatrix's neonatal sepsis diagnostic platform.

• QuantaMatrix unveils world's fastest antimicrobial testing technology backed by research paper in Nature.

• Awarded winner of Sepsis tender from the Great Orchestra of Christmas Charity – WOŚP in Poland.

Rapid, direct-from-positive-blood-culture antimicrobial susceptibility testing to optimize antimicrobial therapy in sepsis and combat antimicrobial resistance.

• dRAST™ (direct & Rapid Antimicrobial Susceptibility Test)

  Rapid AST system providing MIC-based phenotypic results directly from positive blood culture in as low as 4 hours; random access with up to 12 samples simultaneously (15 panel positions); on-board expert system; two panels (Gram-negative and Gram-positive).

• QDST™

  Rapid diagnostic product in QuantaMatrix's pipeline.

• QMAC-dRAST Panel

  96-well plate with panel of dried-down antibiotics at various concentrations.

• QMAC-dRAST Agarose

  Gel used for bacterial immobilization.

• QMAC-dRAST Broth

  Broth used in the dRAST test kit.

1. 1Homepage | QuantaMatrixquantamatrix.com
2. 2About QuantaMatrix | QuantaMatrixquantamatrix.com
3. 3Sepsis Solution - dRAST | QuantaMatrixquantamatrix.com
4. 4Sepsis | QuantaMatrixquantamatrix.com
5. 5QuantaMatrix Inc. - Wikidatawikidata.org